BCHE and Alzheimer disease: Until now, only five drugs have been approved by the Food and Drug Administration (FDA) for the therapy of AD; three of these (donepezil, galantamine, and rivastigmine) are cholinesterase inhibitors, thus suggesting that cholinergic dysfunction plays a critical role in the progression of AD.